Health Canada Approves Eraxis

Pfizer Canada’s Eraxis, a hospital treatment for invasive candidiasis-candidemia in adult non-neutropenic patients, has been approved by Health Canada.

Eraxis (anidulafungin) was shown to be effective in a randomized, double-blind Phase III trial in which anidulafungin was compared with a standard agent, fluconazole.

At the end of intravenous therapy, the success rate was 75.6 percent for anidulafungin compared with 60.2 percent for fluconazole, Pfizer Canada said.

The drug will be available in Canadian hospitals in early 2008.